MFDS Approves New Hepatocellular Carcinoma Drug 'Imudoju'
The Ministry of Food and Drug Safety approved the new drug for hepatocellular carcinoma treatment, 'Imudojoo (Tremelimumab),' on the 23rd.
![[Image source=Yonhap News]](http://www.asiae.co.kr/news/img_view.htm?img=2023041310464687596_1681350406.jpeg)
Imported by Korea AstraZeneca, this drug is used in combination with Imfinzi (Durvalumab) as the first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma. At the first administration, this drug and Imfinzi are given together, and thereafter, only Imfinzi is used alone.
Imudojoo is an antibody that selectively blocks the interaction between CTLA-4 and CD80/CD86, enhancing T cell activation and proliferation to induce T cell antitumor immune responses, providing new treatment opportunities for advanced or unresectable hepatocellular carcinoma.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The Ministry of Food and Drug Safety stated, "We will continue to do our best to ensure that treatments with sufficiently confirmed safety and efficacy are promptly supplied based on regulatory science expertise."
they added.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
